Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Animalcare Group's Days Sales Outstanding for the
six
months ended in Dec. 2025 was 64.11.
Animalcare Group's Days Inventory for the
six
months ended in Dec. 2025 was 136.49.
Animalcare Group's Days Payable for the
six
months ended in Dec. 2025 was 120.09.
Therefore, Animalcare Group's Cash Conversion Cycle (CCC) for the
six
months ended in Dec. 2025 was 80.51.
Animalcare Group (STU:WQ7) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Animalcare Group Cash Conversion Cycle Related Terms
Animalcare Group Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Animalcare Group's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:WQ7 vs ZTS, UTHR, VTRS: Cash Conversion Cycle Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Animalcare Group's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Animalcare Group Cash Conversion Cycle vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Animalcare Group's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Animalcare Group's Cash Conversion Cycle falls into.
Animalcare Group Cash Conversion Cycle Calculation
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Animalcare Group's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Animalcare Group (STU:WQ7) has a Cash Conversion Cycle of 80.51 as of Dec. 2025. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Animalcare Group and its competitors.
Is Animalcare Group's Cash Conversion Cycle too high?
Animalcare Group's current Cash Conversion Cycle is 80.51. The Drug Manufacturers industry median Cash Conversion Cycle is 145.87. Animalcare Group's value of 80.51 is 44.8% below this industry median. Overall, Animalcare Group has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Animalcare Group's Cash Conversion Cycle compare to ZTS and UTHR?
Animalcare Group's Cash Conversion Cycle of 80.51 can be compared against companies in the Drug Manufacturers industry. The industry median Cash Conversion Cycle is 145.87. Animalcare Group's value of 80.51 is 44.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Drug Manufacturers company?
The median Cash Conversion Cycle among Drug Manufacturers companies is 145.87, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Animalcare Group's current Cash Conversion Cycle of 80.51 is 44.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Animalcare Group and its competitors. For the Drug Manufacturers industry, the median Cash Conversion Cycle is 145.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Animalcare Group's current Cash Conversion Cycle is 80.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Animalcare Group stock overvalued right now?
Based on GuruFocus' analysis, Animalcare Group (STU:WQ7) is currently considered Fairly Valued. The stock's GF Value™ is €2.85, compared to a current price of €3.00 — trading 5.3% above its estimated fair value. The current Cash Conversion Cycle is 80.51 and 44.8% below the Drug Manufacturers industry median of 145.87. Animalcare Group's overall GF Score™ is 77/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Animalcare Group (STU:WQ7), the current Cash Conversion Cycle is 80.51 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Animalcare Group (STU:WQ7) Overvalued in 2026?
Based on GuruFocus' analysis, Animalcare Group stock appears to be overvalued.
The current stock price of €3.00 is trading 5.3% above its estimated GF Value™ of €2.85.
GuruFocus considers Animalcare Group to be Fairly Valued.
Key valuation signals for STU:WQ7:
Cash Conversion Cycle: 80.51
GF Value™: €2.85 vs. price of €3.00 (5.3% above fair value)
Industry Position: 44.8% below the Drug Manufacturers median
No single metric tells the full story. See the STU:WQ7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Animalcare Group PLC is active in the healthcare division in the United Kingdom. It is a generic veterinary medicines company. The company mainly caters to veterinary professionals in the treatment of companion animals through a product line comprised of licensed veterinary medicines and companion animal identification products and services. The company operates in Animalcare Europe and Randlab segment. The company derives maximum revenue from the Animalcare Europe segment engaged in development and sale of veterinary pharmaceutical products in Europe and the European International Partners network. Geographically, the company derives maximum revenue from Europe region, followed by Asia-Pacific and other regions.
77GF Score
Get the complete analysis for STU:WQ7
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:WQ7 has been successfully added to your 
